Paul G. Richardson, MD

Paul G. Richardson, MD

Medical Oncology

Languages Spoken:

Arabic, French

Contact Information

Office Phone Number





617-632-3823 (new)


Paul G. Richardson, MD

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma. Subsequent studies have focused on next-generation novel drugs including panobinostat and second-generation proteasome inhibitors including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and a first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma. Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD. This regimen has generated an unprecedented response rate, leading to its adoption in this international study, as well as others in the United States and elsewhere. This particular trial incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy and the optimal positioning of stem cell transplant, with results anticipated in 2021-22. Furthermore, RVD has been established as a backbone to which next-generation agents are being added, including elotuzumab, daratumumab and isatuximab, as well as panobinostat. He has published extensively, having authored or co-authored over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role. Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well as an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple Myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by the second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. He was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the Morse Research Award in 2019.



Clinical Program Leader, Jerome Lipper Multiple Myeloma Center
Director of Clinical Research, Jerome Lipper Multiple Myeloma Center
Institute Physician
RJ Corman Professor of Medicine, Harvard Medical School


Multiple Myeloma Program
Stem Cell Transplantation

Clinical Interests

Experimental therapeutics and cancer pharmacology, Multiple myeloma, Non-myeloid injury including VOD in bone marrow transplantation, Regimen-related toxicity, Stem cell transplantation

Diseases Treated

Board Certification

  • Hematology, 1999
  • Internal Medicine, 1997
  • Medical Oncology, 1998


  • Baystate Medical Center, Tufts University, Hematology & Oncology


  • Beth Israel Deaconess Medical Center, Internal Medicine
  • Newcastle General and Freeman Hospitals, Internal Medicine
  • Royal Marsden Hospital, London, Chief Resident

Medical School

  • University of London, St. Bartholomew's Medical College

Recent Awards

  • Biochemistry Slot Prize,
    Hungarian Prize,
    Honours Colors,
    Wheelwrights Prize,
    Ver Heyden de Lancy Prize: Joint Winner,
    Emil Frei III Fellowship Award,
    Lee Beckenstein Fellowship Award,
    The Society of Teaching Scholars,
    George Canellos Award for Excellence in Clinical Research and Patient Care,
    Partners in Excellence Award,
    Medical Book Competition Award for Multiple Myeloma,
    Tisch Family Outstanding Achievement Award in Translational Research,
    Compassionate Caregiver Award,
    Fellow of the Royal College of Physicians


    Research in Multiple Myeloma, Reduction of Regimen-Related Toxicity

    Under the overall direction and mentorship of Dr. Kenneth Anderson, we are leading several translational efforts in multiple myeloma, including phase I, II, and III clinical trials of new drugs: thalidomide, the thalidomide analog IMiD 3 (also known as lenalidomide, CC-5013, or Revlimid), 2- methoxy estradiol (2-ME2), and the proteasome inhibitor PS 341 (bortezomib or Velcade). Subsequent studies have focused on other novel agents including the histone deacetylase inhibitor SAHA and derivatives of the HSP-90 inhibitor 17-AAG, as well as other small molecules. Our most recent translational research is a phase I trial of the combination of novel agents lenalidomide and bortezomib. In addition to research in myeloma, we have been involved in regimen-related toxicities (RRT), and in particular the development of defibrotide as a novel therapy for hepatic veno-occlusive disease. This work has led to further research in syndromes characterized by endothelial cell injury during high-dose therapy and the study of vascular damage affecting other organ structures, including mucosa. Another important new area of interest in RRT is treatment-emergent neuropathy in myeloma.


    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Dana 1B07 Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Dana 1B07 Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Paul G. Richardson, MD

    About Our Ratings

    Physician Star Rating Comment Block